New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 0.5mg - orodispersible tablet - 0.5 mg - active: risperidone 0.5mg excipient: aspartame carbomer gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 1mg - orodispersible tablet - 1 mg - active: risperidone 1mg excipient: aspartame carbomer gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 2mg; risperidone 2mg - orodispersible tablet - 2 mg - active: risperidone 2mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide active: risperidone 2mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide xanthan gum - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 3mg - orodispersible tablet - 3 mg - active: risperidone 3mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide xanthan gum - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 4mg - orodispersible tablet - 4 mg - active: risperidone 4mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide xanthan gum - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - golimumab 50mg;   - solution for injection - 50 mg - active: golimumab 50mg   excipient: histidine polysorbate 80 sorbitol water for injection - rheumatoid arthritis: simponi, in combination with mtx, is indicated for: · the treatment of active rheumatoid arthritis in adult patients when the response to dmard therapy has been inadequate. · the treatment of active rheumatoid arthritis in adult patients not previously treated with mtx. simponi has also been shown to reduce the rate of progression of joint damage as measured by x-ray, improve physical function and health related quality of life. simponi can be used in patients previously treated with one or more tnf inhibitor(s).

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - golimumab 50mg;   - solution for injection - 50 mg - active: golimumab 50mg   excipient: histidine polysorbate 80 sorbitol water for injection - rheumatoid arthritis: simponi, in combination with mtx, is indicated for: · the treatment of active rheumatoid arthritis in adult patients when the response to dmard therapy has been inadequate. · the treatment of active rheumatoid arthritis in adult patients not previously treated with mtx. simponi has also been shown to reduce the rate of progression of joint damage as measured by x-ray, improve physical function and health related quality of life. simponi can be used in patients previously treated with one or more tnf inhibitor(s).

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - itraconazole 100mg;   - capsule - 100 mg - active: itraconazole 100mg   excipient: erythrosine gelatin   hypromellose indigo carmine macrogol 20000 sugar spheres titanium dioxide - sporanox capsules are indicated for the following conditions: - treatment of vulvovaginal candidiasis. - treatment of pityriasis versicolor. - treatment of dermatomycosis – including highly keratinised regions as in plantar tinea pedis and palmer tinea manus. - treatment of fungal keratitis. - treatment of oral candidiasis. - treatment of onychomycosis caused by dermatophytes and/or yeasts. - systemic mycoses, only in the following fungal infections: o treatment of systemic aspergillosis and candidiasis, o treatment of histoplasmosis, o histoplasmosis, maintenance therapy only in aids patients. o treatment of sporotrichosis (including lymphocutaneous/cutaneous and extracutaneous), o treatment of paracoccidioidomycosis, o treatment of chromomycosis, o treatment of blastomycosis.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - itraconazole 10 mg/ml - oral solution - 10 mg/ml - active: itraconazole 10 mg/ml excipient: caramel cherry flavour 654536 cherry flavour 654595 hydrochloric acid hydroxypropyl-beta-cyclodextrin propylene glycol purified water saccharin sodium sodium hydroxide sorbitol - sporanox oral solution is indicated for the: · treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. · prophylaxis of fungal infections in neutropenic patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ustekinumab 45mg;   - solution for injection - 45 mg - active: ustekinumab 45mg   excipient: histidine as hydrochloride polysorbate 80 sucrose water for injection - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.